Description
SWOT ANALYSIS OF VALEANT PHARMACEUTICALS
Valeant Pharmaceuticals
Parent Company
Valeant Pharmaceuticals International
Category
Pharmaceutical
Sector
Healthcare
Tagline/ Slogan
Multinational specialty pharmaceutical company
USP
It is leading company in neurology & dermatology segments
STP
Segment
Dermatology, neurology & ophthalmic segment
Healthcare professionals, patients & hospitals operating in these Target Group segments
Positioning
It is diversifies specialty pharmaceutical company
SWOT Analysis
1. It has over 7500 employees in the organization 2. It has broad product base with over 900 products 3. It has strong product pipeline with many molecules in last stages of development 4. Their recent acquisitions have further strengthened their presence in generic market 5. Specialization in neurology and dermatology Strength 6. Manufacturing sites in Canada, Brazil, Poland and Mexico
1. Company has limited presence in emerging markets which has huge potential Weakness 2. Largely dependent upon America for revenue generation
1. Opportunity to grow in new markets such as Russia & Brazil through acquisitions 2. Strong growth in generics & OTC drugs Opportunity 3. Increasing ageing populations
Threats
1. US healthcare reforms
2. Economic slowdown reducing spend on healthcare 3. Strong competition in branded drugs segments
Competition
1. Forest labs 2. Allergen 3. Roche pharmaceuticals Competitors 4. Novartis
doc_530081874.docx
SWOT ANALYSIS OF VALEANT PHARMACEUTICALS
Valeant Pharmaceuticals
Parent Company
Valeant Pharmaceuticals International
Category
Pharmaceutical
Sector
Healthcare
Tagline/ Slogan
Multinational specialty pharmaceutical company
USP
It is leading company in neurology & dermatology segments
STP
Segment
Dermatology, neurology & ophthalmic segment
Healthcare professionals, patients & hospitals operating in these Target Group segments
Positioning
It is diversifies specialty pharmaceutical company
SWOT Analysis
1. It has over 7500 employees in the organization 2. It has broad product base with over 900 products 3. It has strong product pipeline with many molecules in last stages of development 4. Their recent acquisitions have further strengthened their presence in generic market 5. Specialization in neurology and dermatology Strength 6. Manufacturing sites in Canada, Brazil, Poland and Mexico
1. Company has limited presence in emerging markets which has huge potential Weakness 2. Largely dependent upon America for revenue generation
1. Opportunity to grow in new markets such as Russia & Brazil through acquisitions 2. Strong growth in generics & OTC drugs Opportunity 3. Increasing ageing populations
Threats
1. US healthcare reforms
2. Economic slowdown reducing spend on healthcare 3. Strong competition in branded drugs segments
Competition
1. Forest labs 2. Allergen 3. Roche pharmaceuticals Competitors 4. Novartis
doc_530081874.docx